© Reuters.
In a recent series of transactions, Steve Elms, a director at ADMA Biologics, Inc. (NASDAQ:), sold a significant portion of his holdings in the company. Over the course of three days, Elms disposed of shares with a total value exceeding $6.3 million, according to the latest filings with the Securities and Exchange Commission.
The transactions took place between March 13 and March 15, with Elms selling 407,000 shares on the first day at an average price of $6.21 per share. The following day, he sold an additional 448,276 shares for an average price of $6.05 each. On the final day, 183,008 shares were sold at an average price of $6.01. The price range for these sales varied from $6.01 to $6.21.
After these sales, Elms still indirectly owns a substantial number of shares in ADMA Biologics. The indirect nature of the ownership is due to his association with Aisling Capital II LP, where he serves as a managing member and is on the investment committee. Elms has disclaimed beneficial ownership of these shares, except to the extent of his pecuniary interest.
The transactions have been made public as part of the regulatory requirements, providing investors insight into the trading activities of the company’s insiders. It is not uncommon for executives and directors to sell shares for various personal financial planning reasons, and such sales are closely watched by the market for indications of their confidence in the company’s future prospects.
ADMA Biologics, based in Ramsey, New Jersey, specializes in the development and manufacturing of plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s stock is traded under the ticker symbol ADMA on the NASDAQ stock exchange.
InvestingPro Insights
Amidst the recent insider trading activities at ADMA Biologics, Inc., it’s crucial for investors to consider the company’s financial health and market performance. According to InvestingPro data, ADMA Biologics has a market capitalization of $1.37 billion. The company has experienced a substantial revenue growth of 67.59% over the last twelve months as of Q4 2023, with a gross profit margin of 35.26%. Despite these promising figures, the company’s P/E ratio stands at a negative 47.74, indicating that the company has not been profitable over the last twelve months.
However, the recent price movements paint a more optimistic picture for ADMA Biologics. The company’s stock has provided a strong return of 91.37% over the last year and is trading near its 52-week high, at 93.37% of that value. This suggests a bullish sentiment among investors, as reflected in the stock’s performance.
InvestingPro Tips also reveal that analysts predict ADMA Biologics will become profitable this year, which could be a pivotal factor for future stock appreciation. Additionally, the company’s liquid assets exceed its short-term obligations, providing financial stability and the ability to meet its immediate liabilities.
For those looking to delve deeper into ADMA Biologics’ financials and gain further insights, InvestingPro offers additional tips. There are currently 13 more InvestingPro Tips available, which can provide a more comprehensive view of the company’s potential. Interested investors can explore these tips by visiting the dedicated page for ADMA Biologics on InvestingPro. Moreover, users can take advantage of a special offer by using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enhancing their investment research tools.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
